Trial · NCT01203852

Pharmacogenomic Evaluation of Antihypertensive Responses 2

NCT01203852, Phase 4, Completed, University of Florida; results first posted 2015-05-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pharmacogenomic Evaluation of Antihypertensive Responses 2. Trials, record NCT01203852. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01203852

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pharmacogenomic Evaluation of Antihypertensive Responses 2
NCT number: NCT01203852
Status: Completed
Phases: Phase 4
Enrollment: 839 participants, actual
Lead sponsor: University of Florida
Conditions: Hypertension
Interventions: Metoprolol, Chlorthalidone
First posted: 2010-09-16
Last updated: 2018-04-06
Results first posted: 2015-05-19

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Blood Pressure From Baseline to Treatment	after 6-8 weeks of treatment	Response to blood pressure medication will be assessed by measuring blood pressure before and after treatment
Secondary	Adverse Metabolic Effects	after 6-8 weeks treatment	Change in glucose after treatment with study medication

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Blood Pressure From Baseline to Treatment	after 6-8 weeks of treatment	All patients with antihypertensive response data. 282 patients completed all 3 study periods. 369 patients completed only period 1. 328 patients completed only period 3.	mmHg	MEAN
SECONDARY	Adverse Metabolic Effects	after 6-8 weeks treatment	All patients with change in glucose data	mg/dL	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Blood Pressure From Baseline to Treatment	Metoprolol + Chlorthalidone	diastolic blood pressure response	-7.56	Standard Deviation 6.39	mmHg
Change in Blood Pressure From Baseline to Treatment	Metorprolol Only	diastolic blood pressure response	-7.97	Standard Deviation 6.48	mmHg
Change in Blood Pressure From Baseline to Treatment	Chlorthalidone Only	diastolic blood pressure response	-7.68	Standard Deviation 5.84	mmHg
Change in Blood Pressure From Baseline to Treatment	Metoprolol + Chlorthalidone	systolic blood pressure response	-11.70	Standard Deviation 9.51	mmHg
Change in Blood Pressure From Baseline to Treatment	Metorprolol Only	systolic blood pressure response	-7.45	Standard Deviation 9.85	mmHg
Change in Blood Pressure From Baseline to Treatment	Chlorthalidone Only	systolic blood pressure response	-13.65	Standard Deviation 9.55	mmHg
Adverse Metabolic Effects	Adverse Metabolic Effects	glucose response to metoprolol (n=365)	1.02	Standard Deviation 9.83	mg/dL
Adverse Metabolic Effects	Adverse Metabolic Effects	glucose response to chlorthalidone (n=318)	5.12	Standard Deviation 10.6	mg/dL

Source ClinicalTrials.gov

Participant flow10

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Metoprolol 8 Weeks	STARTED	Metoprolol + Chlorthalidone	839
Metoprolol 8 Weeks	COMPLETED	Metoprolol + Chlorthalidone	369
Metoprolol 8 Weeks	NOT COMPLETED	Metoprolol + Chlorthalidone	470
Washout 2 Weeks	STARTED	Metoprolol + Chlorthalidone	328
Washout 2 Weeks	COMPLETED	Metoprolol + Chlorthalidone	282
Washout 2 Weeks	NOT COMPLETED	Metoprolol + Chlorthalidone	46
Chlorthalidone 8 Weeks	STARTED	Metoprolol + Chlorthalidone	328
Chlorthalidone 8 Weeks	Continued From Metoprolol	Metoprolol + Chlorthalidone	282
Chlorthalidone 8 Weeks	COMPLETED	Metoprolol + Chlorthalidone	328
Chlorthalidone 8 Weeks	NOT COMPLETED	Metoprolol + Chlorthalidone	0

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Bradycardia	Cardiac disorders	All Study Participants	2	839	2
other	Chest Pain	Cardiac disorders	All Study Participants	2	839	2
other	Diarrhea	Gastrointestinal disorders	All Study Participants	4	839	4
other	Dizziness	Ear and labyrinth disorders	All Study Participants	10	839	11
other	Dyspnea	Nervous system disorders	All Study Participants	1	839	1
other	Headache	Vascular disorders	All Study Participants	29	839	32
other	Nausea	Gastrointestinal disorders	All Study Participants	7	839	8
other	Rash	Skin and subcutaneous tissue disorders	All Study Participants	3	839	3
other	Fatigue	General disorders	All Study Participants	15	839	16
other	Other	General disorders	All Study Participants	41	839	55

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	All Study Participants
Total, other adverse events	All Study Participants	114	839
Total, serious adverse events	All Study Participants	3	839

Source ClinicalTrials.gov

Papers7

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
24637943	BACKGROUND	PubMed
28115488	DERIVED	PubMed
29523524	DERIVED	PubMed
29925376	DERIVED	PubMed
30753254	DERIVED	PubMed
38353215	DERIVED	PubMed
38747311	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U01GM074492	Pharmacogenomic Evaluation of Antihypertensive Responses	JOHNSON, JULIE A.; COOPER-DEHOFF, RHONDA M	UNIVERSITY OF FLORIDA	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES	2005 to 2014

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01203852

GET https://conductscience.org/api/trials/v1/NCT01203852/registered

API reference For AI assistants